Veregen is a drug owned by Ani Pharmaceuticals Inc. It is protected by 5 US drug patents filed from 2013 to 2019. Out of these, 2 drug patents are active and 3 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 02, 2026. Details of Veregen's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7858662 | Medicament for the treatment of viral skin and tumour diseases |
Oct, 2026
(1 year, 10 months from now) | Active |
| US9770406 | Medicament for the treatment of viral skin and tumour diseases |
Jul, 2025
(7 months from now) | Active |
| US10434059 | Medicament for the treatment of viral skin and tumour diseases |
Nov, 2022
(2 years ago) |
Expired
|
| US5795911 | Composition for treating Condyloma acuminata |
Oct, 2020
(4 years ago) |
Expired
|
| US5968973 | Method for treating hyperplasia |
Apr, 2017
(7 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Veregen's patents.
Latest Legal Activities on Veregen's Patents
Given below is the list of recent legal activities going on the following patents of Veregen.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 13 Nov, 2023 | US10434059 |
| Maintenance Fee Reminder Mailed Critical | 29 May, 2023 | US10434059 |
| Expire Patent Critical | 30 Jan, 2023 | US7858662 |
| Maintenance Fee Reminder Mailed Critical | 15 Aug, 2022 | US7858662 |
| Surcharge for Late Payment, Large Entity | 14 Jul, 2021 | US9770406 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Jul, 2021 | US9770406 |
| Maintenance Fee Reminder Mailed Critical | 17 May, 2021 | US9770406 |
| Recordation of Patent Grant Mailed Critical | 08 Oct, 2019 | US10434059 |
| Patent Issue Date Used in PTA Calculation Critical | 08 Oct, 2019 | US10434059 |
| Email Notification Critical | 19 Sep, 2019 | US10434059 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Veregen and ongoing litigations to help you estimate the early arrival of Veregen generic.
Veregen's Litigations
Veregen been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Sep 08, 2015, against patent number US9770406. The petitioner , challenged the validity of this patent, with Yunik Chang et al as the respondent. Click below to track the latest information on how companies are challenging Veregen's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9770406 | September, 2015 |
Decision
(07 Feb, 2017) | Yunik Chang et al | |
US patents provide insights into the exclusivity only within the United States, but Veregen is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Veregen's family patents as well as insights into ongoing legal events on those patents.
Veregen's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Veregen's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 02, 2026 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Veregen Generics:
There are no approved generic versions for Veregen as of now.
Alternative Brands for Veregen
Veregen which is used for treating genital warts., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Bausch |
| |||
About Veregen
Veregen is a drug owned by Ani Pharmaceuticals Inc. It is used for treating genital warts. Veregen uses Sinecatechins as an active ingredient. Veregen was launched by Ani Pharms in 2006.
Approval Date:
Veregen was approved by FDA for market use on 31 October, 2006.
Active Ingredient:
Veregen uses Sinecatechins as the active ingredient. Check out other Drugs and Companies using Sinecatechins ingredient
Treatment:
Veregen is used for treating genital warts.
Dosage:
Veregen is available in ointment form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 15% | OINTMENT | Prescription | TOPICAL |